Oxford Immunotec Global PLC (OXFD) Position Increased by Renaissance Technologies LLC

Renaissance Technologies LLC boosted its position in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 97.8% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 363,300 shares of the company’s stock after buying an additional 179,600 shares during the period. Renaissance Technologies LLC owned 1.60% of Oxford Immunotec Global PLC worth $5,628,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Neuberger Berman Group LLC boosted its stake in Oxford Immunotec Global PLC by 143.6% in the first quarter. Neuberger Berman Group LLC now owns 134,229 shares of the company’s stock worth $2,079,000 after buying an additional 79,129 shares in the last quarter. American International Group Inc. boosted its stake in Oxford Immunotec Global PLC by 7.1% in the first quarter. American International Group Inc. now owns 13,668 shares of the company’s stock worth $212,000 after buying an additional 904 shares in the last quarter. TFS Capital LLC boosted its stake in Oxford Immunotec Global PLC by 19.8% in the first quarter. TFS Capital LLC now owns 14,125 shares of the company’s stock worth $219,000 after buying an additional 2,337 shares in the last quarter. Denver Investment Advisors LLC boosted its stake in Oxford Immunotec Global PLC by 47.5% in the first quarter. Denver Investment Advisors LLC now owns 30,880 shares of the company’s stock worth $478,000 after buying an additional 9,949 shares in the last quarter. Finally, Parkwood LLC purchased a new stake in Oxford Immunotec Global PLC during the first quarter worth $176,000. Institutional investors and hedge funds own 84.96% of the company’s stock.

Shares of Oxford Immunotec Global PLC (NASDAQ OXFD) opened at 15.05 on Friday. Oxford Immunotec Global PLC has a 1-year low of $9.49 and a 1-year high of $19.51. The company has a 50-day moving average of $16.78 and a 200-day moving average of $15.22. The firm’s market capitalization is $347.29 million.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last announced its quarterly earnings results on Tuesday, August 1st. The company reported ($0.32) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.32). The company had revenue of $26.10 million for the quarter, compared to analyst estimates of $25.05 million. Oxford Immunotec Global PLC had a negative net margin of 34.58% and a negative return on equity of 35.76%. The firm’s revenue was up 35.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.29) earnings per share. Equities research analysts predict that Oxford Immunotec Global PLC will post ($1.63) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Oxford Immunotec Global PLC (OXFD) Position Increased by Renaissance Technologies LLC” was first published by BNB Daily and is the property of of BNB Daily. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.baseball-news-blog.com/2017/08/19/oxford-immunotec-global-plc-oxfd-stake-increased-by-renaissance-technologies-llc-updated-updated.html.

A number of analysts have recently weighed in on the stock. Zacks Investment Research cut shares of Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Cowen and Company restated a “buy” rating and issued a $22.00 price target on shares of Oxford Immunotec Global PLC in a report on Thursday, August 3rd. Piper Jaffray Companies restated a “buy” rating and issued a $26.00 price target on shares of Oxford Immunotec Global PLC in a report on Thursday, August 3rd. ValuEngine upgraded shares of Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, BTIG Research restated a “buy” rating on shares of Oxford Immunotec Global PLC in a report on Thursday, May 4th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. Oxford Immunotec Global PLC currently has an average rating of “Hold” and a consensus target price of $20.25.

In other news, VP Elizabeth M. Keiley sold 4,085 shares of the stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $15.01, for a total value of $61,315.85. Following the completion of the sale, the vice president now directly owns 25,393 shares of the company’s stock, valued at $381,148.93. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Peter Wrighton-Smith sold 27,168 shares of the stock in a transaction that occurred on Thursday, July 6th. The shares were sold at an average price of $15.94, for a total value of $433,057.92. Following the completion of the sale, the chief executive officer now directly owns 488,836 shares of the company’s stock, valued at $7,792,045.84. The disclosure for this sale can be found here. Insiders sold 126,195 shares of company stock worth $2,073,682 over the last quarter. 7.58% of the stock is currently owned by insiders.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Institutional Ownership by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply